ALT
Altimmune, Inc.
$2.90
-0.03
(-1.02%)
Mkt Cap
255.95M
Volume
1,988,383
52W Range
2.56-7.73
Sector
Healthcare
Beta
0.17
EPS (TTM)
-0.93
P/E Ratio
-3.61
Revenue (TTM)
36,000
Rev Growth (5Y)
-65.3%
EPS Growth (5Y)
N/A
Company Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41,000 | 20,000 | 426,000 | (68,000) | 4.41M | 8.19M | 5.80M | 10.33M | 41,503 | 5.23M | 10.64M | 10.19M |
| Net Income | (88.09M) | (95.06M) | (88.45M) | (84.71M) | (97.09M) | (49.04M) | (20.52M) | (39.17M) | (46.43M) | 193.85M | (3.44M) | (9.96M) |
| EPS | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 |
| Free Cash Flow | (67.55M) | (79.85M) | (75.86M) | (62.71M) | (90.55M) | (34.65M) | (9.60M) | (10.40M) | (20.38M) | 201.48M | N/A | N/A |
| FCF / Share | -0.77 | -1.12 | -1.42 | -1.34 | -2.19 | -1.35 | -0.73 | -3.71 | -47.75 | 874.54 | N/A | N/A |
| Operating CF | (67.53M) | (79.85M) | (75.81M) | (62.59M) | (78.24M) | (34.31M) | (9.60M) | (9.39M) | (20.21M) | 201.51M | N/A | N/A |
| Total Assets | 279.93M | 139.31M | 210.64M | 206.93M | 218.87M | 245.12M | 54.06M | 54.75M | 63.03M | 224.74M | N/A | N/A |
| Total Debt | 35.69M | 1.68M | 671,000 | 1.12M | 1.53M | 1.82M | 1.74M | 572,770 | 49,702 | 984,580 | N/A | N/A |
| Cash & Equiv | 43.76M | 36.93M | 135.12M | 111.10M | 190.30M | 115.92M | 8.96M | 33.72M | 8.77M | 153.99M | N/A | N/A |
| Book Value | 224.89M | 123.51M | 194.10M | 185.29M | 199.13M | 225.88M | 45.52M | 48.31M | 48.68M | 19.46M | N/A | N/A |
| Return on Equity | -0.39 | -0.77 | -0.46 | -0.46 | -0.49 | -0.22 | -0.45 | -0.81 | -0.95 | 9.96 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 26,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 37,000 | 362,000 | 6,000 |
| Net Income | (22.56M) | (27.36M) | (19.01M) | (22.15M) | (19.57M) | (23.18M) | (22.84M) | (24.64M) | (24.39M) | (31.64M) | (20.67M) | (16.06M) |
| EPS | -0.18 | -0.27 | -0.21 | -0.27 | -0.26 | -0.33 | -0.32 | -0.35 | -0.34 | -0.54 | -0.39 | -0.32 |
| Free Cash Flow | (20.96M) | (19.45M) | (11.90M) | (19.66M) | (16.84M) | (18.27M) | (27.12M) | (18.11M) | (16.36M) | (16.53M) | (20.49M) | (19.56M) |
| FCF / Share | -0.17 | -0.19 | -0.13 | -0.24 | -0.22 | -0.26 | -0.38 | -0.26 | -0.23 | -0.28 | -0.38 | -0.39 |
| Operating CF | (20.94M) | (19.45M) | (11.90M) | (19.65M) | (16.84M) | (18.27M) | (27.12M) | (18.11M) | (16.36M) | (16.53M) | (20.49M) | (19.57M) |
| Total Assets | 335.63M | 279.93M | 218.45M | 190.35M | 157.26M | 139.31M | 147.86M | 173.35M | 188.36M | 210.64M | 166.57M | 183.32M |
| Total Debt | 35.85M | 35.69M | 15.90M | 15.85M | 1.59M | 1.68M | 1.77M | 1.86M | 552,000 | 671,000 | 788,000 | 903,000 |
| Cash & Equiv | 97.60M | 43.76M | 61.24M | 183.10M | 49.10M | 36.93M | 31.47M | 57.13M | 78.98M | 135.12M | 86.86M | 102.35M |
| Book Value | 283.99M | 224.89M | 185.60M | 161.37M | 142.16M | 123.51M | 133.38M | 152.53M | 172.94M | 194.10M | 150.40M | 167.71M |
| Return on Equity | -0.08 | -0.12 | -0.10 | -0.14 | -0.14 | -0.19 | -0.17 | -0.16 | -0.14 | -0.16 | -0.14 | -0.10 |
ALT News
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Altimmune Q1 Earnings Call Highlights
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
AI Financial Corporation (Formerly ALT5 Sigma) Begins Trading Under New Nasdaq Ticker Symbol 'AIFC'
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities